STOCK ANALYSIS | OCTOBER 28, 2026 CareDx is growing revenue like a company that has discovered the secret to printing money. Unfortunately, once I started examining organic growth, reimbursement, and adjusted earnings, I discovered that Wall Street's favorite numbers deserve a few uncomfortable questions. Stock: CDNA | Sector: Healthcare | Industry: Precision Diagnostics Wall Street Saw 52% Revenue Growth and Immediately Started Planning the Celebration I have a confession to make. Whenever I see a company announcing 52% revenue growth, my first instinct is to get excited. My second instinct is to figure out what management isn't emphasizing quite as enthusiastically. That's not because I'm naturally pessimistic. It's because I've spent enough time following public companies to understand that financial statements occasionally resemble online dating profiles. Everything presented might technically be true, but there are usually a few details worth investigating ...
Today's Investing Article | October 27, 2026 Category: Stock Analysis After reporting stronger sales, improving profit margins, and raising its earnings outlook, Coca-Cola has demonstrated why investors continue paying a premium for its shares. But with the stock up approximately 33% this year, the real question is whether the company's growth can justify its increasingly demanding valuation. There is something remarkable about a company that can sell essentially the same flagship product for more than a century and still convince investors that its best opportunities lie ahead. Most businesses spend enormous amounts of money trying to reinvent themselves. Coca-Cola has spent generations persuading people to keep buying something they already know, recognize, and occasionally insist tastes better from a glass bottle. That may sound like a relatively simple business model, but simplicity can be extraordinarily profitable when combined with global distribution, powerful brands, a...